Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

CD4+ T cell activation and associated susceptibility to HIV-1 infection in vitro increased following acute resistance exercise in human subjects.

Holbrook AK, Peterson HD, Bianchi SA, Macdonald BW, Bredahl EC, Belshan M, Siedlik JA.

Physiol Rep. 2019 Sep;7(18):e14234. doi: 10.14814/phy2.14234.

2.

A potential long-acting bictegravir loaded nano-drug delivery system for HIV-1 infection: A proof-of-concept study.

Mandal S, Prathipati PK, Belshan M, Destache CJ.

Antiviral Res. 2019 Jul;167:83-88. doi: 10.1016/j.antiviral.2019.04.007. Epub 2019 Apr 13.

PMID:
30991088
3.

Proteomic profiling of HIV-infected T-cells by SWATH mass spectrometry.

DeBoer J, Wojtkiewicz MS, Haverland N, Li Y, Harwood E, Leshen E, George JW, Ciborowski P, Belshan M.

Virology. 2018 Mar;516:246-257. doi: 10.1016/j.virol.2018.01.025.

4.

An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection.

Mandal S, Belshan M, Holec A, Zhou Y, Destache CJ.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01475-16. doi: 10.1128/AAC.01475-16. Print 2017 Jan.

5.

NF45 and NF90 Bind HIV-1 RNA and Modulate HIV Gene Expression.

Li Y, Belshan M.

Viruses. 2016 Feb 16;8(2). pii: E47. doi: 10.3390/v8020047.

6.

Cyclophilin B enhances HIV-1 infection.

DeBoer J, Madson CJ, Belshan M.

Virology. 2016 Feb;489:282-91. doi: 10.1016/j.virol.2015.12.015. Epub 2016 Jan 14.

7.

Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Oct 16;11(10):e1005170. doi: 10.1371/journal.ppat.1005170. eCollection 2015 Oct. No abstract available.

8.

Investigation of the HIV-1 matrix interactome during virus replication.

Li Y, Frederick KM, Haverland NA, Ciborowski P, Belshan M.

Proteomics Clin Appl. 2016 Feb;10(2):156-63. doi: 10.1002/prca.201400189. Epub 2015 Nov 16.

9.

Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Date AA, Shibata A, McMullen E, La Bruzzo K, Bruck P, Belshan M, Zhou Y, Destache CJ.

J Biomed Nanotechnol. 2015 Mar;11(3):416-27.

10.

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Aug 13;11(8):e1005075. doi: 10.1371/journal.ppat.1005075. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005170. Nochii, Tomonori [corrected to Nochi, Tomonori].

11.

Alterations in the nuclear proteome of HIV-1 infected T-cells.

DeBoer J, Jagadish T, Haverland NA, Madson CJ, Ciborowski P, Belshan M.

Virology. 2014 Nov;468-470:409-420. doi: 10.1016/j.virol.2014.08.029. Epub 2014 Sep 19.

12.

Deletions in the fifth alpha helix of HIV-1 matrix block virus release.

Sanford B, Li Y, Maly CJ, Madson CJ, Chen H, Zhou Y, Belshan M.

Virology. 2014 Nov;468-470:293-302. doi: 10.1016/j.virol.2014.08.017. Epub 2014 Sep 15.

13.

Identification of low molecular weight nuclear complexes containing integrase during the early stages of HIV-1 infection.

Gérard A, Soler N, Ségéral E, Belshan M, Emiliani S.

Retrovirology. 2013 Feb 1;10:13. doi: 10.1186/1742-4690-10-13.

14.

Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, Goede M, Date AA, Destache CJ.

AIDS Res Hum Retroviruses. 2013 May;29(5):746-54. doi: 10.1089/AID.2012.0301. Epub 2013 Feb 1. Erratum in: AIDS Res Hum Retroviruses. 2013 Jul;29(7):1095. Date, Abjijit A [corrected to Date, Abhijit A].

15.

Proteomic analysis of early HIV-1 nucleoprotein complexes.

Schweitzer CJ, Jagadish T, Haverland N, Ciborowski P, Belshan M.

J Proteome Res. 2013 Feb 1;12(2):559-72. doi: 10.1021/pr300869h. Epub 2013 Jan 16.

16.

Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.

Date AA, Shibata A, Goede M, Sanford B, La Bruzzo K, Belshan M, Destache CJ.

Antiviral Res. 2012 Dec;96(3):430-6. doi: 10.1016/j.antiviral.2012.09.015. Epub 2012 Oct 3.

17.

Knockdown of the cellular protein LRPPRC attenuates HIV-1 infection.

Schweitzer CJ, Matthews JM, Madson CJ, Donnellan MR, Cerny RL, Belshan M.

PLoS One. 2012;7(7):e40537. doi: 10.1371/journal.pone.0040537. Epub 2012 Jul 12.

18.

Vpx is critical for SIVmne infection of pigtail macaques.

Belshan M, Kimata JT, Brown C, Cheng X, McCulley A, Larsen A, Thippeshappa R, Hodara V, Giavedoni L, Hirsch V, Ratner L.

Retrovirology. 2012 Apr 24;9:32. doi: 10.1186/1742-4690-9-32.

19.

Replication of biotinylated human immunodeficiency viruses.

Belshan M, Matthews JM, Madson CJ.

J Virol Methods. 2011 Jan;171(1):299-302. doi: 10.1016/j.jviromet.2010.11.005. Epub 2010 Nov 16.

20.

Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA.

J Antimicrob Chemother. 2010 Oct;65(10):2183-7. doi: 10.1093/jac/dkq318. Epub 2010 Aug 21.

21.

In vivo biotinylation and capture of HIV-1 matrix and integrase proteins.

Belshan M, Schweitzer CJ, Donnellan MR, Lu R, Engelman A.

J Virol Methods. 2009 Aug;159(2):178-84. doi: 10.1016/j.jviromet.2009.03.017. Epub 2009 Mar 26.

22.
23.

Characterization of functional domains of equine infectious anemia virus Rev suggests a bipartite RNA-binding domain.

Lee JH, Murphy SC, Belshan M, Sparks WO, Wannemuehler Y, Liu S, Hope TJ, Dobbs D, Carpenter S.

J Virol. 2006 Apr;80(8):3844-52.

24.

Analysis of HIV-2 Vpx by modeling and insertional mutagenesis.

Mahnke LA, Belshan M, Ratner L.

Virology. 2006 Apr 25;348(1):165-74. Epub 2006 Feb 7.

26.

Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Baccam P, Thompson RJ, Li Y, Sparks WO, Belshan M, Dorman KS, Wannemuehler Y, Oaks JL, Cornette JL, Carpenter S.

J Virol. 2003 Nov;77(22):12122-31.

27.
28.

Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.

Belshan M, Baccam P, Oaks JL, Sponseller BA, Murphy SC, Cornette J, Carpenter S.

Virology. 2001 Jan 5;279(1):185-200.

29.
30.

Biological characterization of Rev variation in equine infectious anemia virus.

Belshan M, Harris ME, Shoemaker AE, Hope TJ, Carpenter S.

J Virol. 1998 May;72(5):4421-6.

Supplemental Content

Loading ...
Support Center